A Prospective, Multi-Center, Double-Blind, Randomized, Placebo-Controlled Trial Comparing Two Doses of VF001-DP to Placebo as an Adjunct to Standard Care in Patients With Chronic Venous Leg Ulcers
Latest Information Update: 03 Sep 2020
Price :
$35 *
At a glance
- Drugs VF 001 (Primary)
- Indications Varicose ulcer
- Focus Therapeutic Use
- Sponsors Factor Therapeutics
- 01 Oct 2018 According to a Factor Therapeutics media release, the last treatment visit is expected in the coming week triggering final data cleaning before results analysis. Top-line results are expected in mid-November.
- 05 Sep 2018 According to Factor Therapeutics media release,The Company is currently targeting top-line data release in mid-November.
- 05 Sep 2018 According to a Factor Therapeutics media release, trial is approaching the end of its treatment phase.